Type: Oral
Session: 803. Emerging Tools, Techniques, and Artificial Intelligence in Hematology: New Approaches to Predicting Patient Outcomes in Hematologic Malignancies
Hematology Disease Topics & Pathways:
Artificial intelligence (AI), MDS, Research, Adult, Elderly, Translational Research, Clinical Research, Bioinformatics, Genomics, Chronic Myeloid Malignancies, Diseases, Real-world evidence, Myeloid Malignancies, Biological Processes, Emerging technologies, Technology and Procedures, Human, Study Population, Multi-systemic interactions, Imaging, Omics technologies
Aim. In this scenario, we developed MEGAERA, an innovative, deep learning-based framework for multimodal analysis of hematological malignancies. MEGAERA integrates clinical, multi-omics, and histopathological data, using specific strategies to ensure full clinical explainability and interpretability of predictions. This study was conducted by the GenoMed4All and Synthema EU consortia, with MDS included as use case, to improve personalized predictions of patient outcomes.
Methods. The study population consisted of 605 MDS patients from Humanitas Research Hospital. For these patients, multi-modal data were available, including clinical characteristics, cytogenetics, somatic mutation screening on 31 genes, bulk RNA-seq of CD34+ bone marrow (BM) cells, and deep flow cytometry evaluation of T lymphocytes, natural killer and myeloid cells. Whole slide images (WSI) of BM biopsies stained with Hematoxylin and Eosin (H&E) and May-Grunwald Giemsa (MGG) were also retrieved. Comprehensive information on treatments and clinical outcomes was collected.
MEGAERA deep-learning workflow involves two processing layers. The first one exploits a custom fine-tuned implementation of Prov-GigaPath for WSI segmentation and features extraction. The second layer uses Self-Normalizing Networks with two hidden layers for handling clinical and molecular profiles. All the processed variables are combined and fed into a fusion model that correlates them to clinical outcomes. Explainability was implemented using attention-based maps for WSI and Shapley Additive Explanations Approach for feature importance rankings. The predictive ability of the approach was assessed using Harrell’s concordance index (CI).
Results. We used Prov-GigaPath on BM WSI for extracting morphological features. Prov-GigaPath outperformed current state-of-the-art methods including ResNet50 and DinoBloom, achieving 10% improvement of CI.
We evaluated MAGAERA’s predictive performance on MDS population, analyzing the multimodal integration alongside unimodal contributions, with Overall Survival (OS) as primary endpoint. Sequential integration of data modalities into the model showed an increasing CI for OS: starting with 0.56 CI considering clinical information alone, then rising to 0.81 CI by including cytogenetic, genomic, transcriptomic and immunologic signatures, and finally reaching 0.85 CI with morphological features integration. Our fusion model significantly enhanced the performance of conventional IPSS-R (0.68) and IPSS-M (0.76) scores. Similar improvements were observed in predicting leukemic evolution risk (0.83) and the individual probability of response to HMA treatment (0.84).
An extensive validation of the model’s performance was performed using multimodal synthetic data (PMID: 37390377), reaching comparable CI. To facilitate the clinical implementation of this framework, we are exploring innovative AI-based dimensionality reduction and inference approaches, to enable model’s knowledge transfer to patients lacking information collected outside diagnostic routine tests.
Conclusion. The MEGAERA multimodal fusion model demonstrated improved clinical outcome prediction in MDS patients. Our approach leverages full interpretability to elucidate features contribution to risk prediction. This framework is expected to significantly enhance clinical decision-making in MDS by supporting the implementation of personalized medicine programs.
Disclosures: Santoro: Sanofi: Consultancy; Incyte: Consultancy; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servier: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Gilead: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Pfizer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; EISAI: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Bayer: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; MSD: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Takeda: Speakers Bureau; Roche: Speakers Bureau; Abb-vie: Speakers Bureau; Amgen: Speakers Bureau; Celgene: Speakers Bureau; Astrazeneca: Speakers Bureau; Arqule: Speakers Bureau; Lilly: Speakers Bureau; Sandoz: Speakers Bureau; Novartis: Speakers Bureau; Beigene: Speakers Bureau. Santini: Ascentage, AbbVie, Bristol Myers Squibb, CTI BioPharma, Geron, Gilead, Novartis, Servier, Syros Pharmaceuticals: Other: Advisory Board. Platzbecker: Amgen: Consultancy, Research Funding; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Travel support, Research Funding; MDS Foundation: Membership on an entity's Board of Directors or advisory committees; Abbvie: Consultancy, Research Funding; Curis: Consultancy, Honoraria, Research Funding; Geron: Consultancy; Janssen: Consultancy, Honoraria, Research Funding; Merck: Research Funding; Novartis: Consultancy, Research Funding. Fenaux: Novartis: Research Funding; Janssen: Research Funding; Jazz Pharmaceuticals: Honoraria, Research Funding; Agios: Research Funding; Servier: Research Funding; Astex: Research Funding; AbbVie: Honoraria, Research Funding; BMS: Honoraria, Research Funding. Diez-Campelo: Gilead: Other: Travel reimbursement; BLUEPRINT MEDICINES: Consultancy, Membership on an entity's Board of Directors or advisory committees; KEROS: Honoraria, Membership on an entity's Board of Directors or advisory committees; SYROS: Membership on an entity's Board of Directors or advisory committees; HEMAVAN: Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; GSK: Consultancy, Membership on an entity's Board of Directors or advisory committees; ASTEX/OTSUKA: Membership on an entity's Board of Directors or advisory committees, Other: TRAVEL TO MEETINGS; CURIS: Membership on an entity's Board of Directors or advisory committees; AGIOS: Consultancy, Membership on an entity's Board of Directors or advisory committees; BMS/Celgene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Advisory board fees. Komrokji: Genentech: Consultancy; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Taiho: Membership on an entity's Board of Directors or advisory committees; Keros: Membership on an entity's Board of Directors or advisory committees; DSI: Consultancy, Membership on an entity's Board of Directors or advisory committees; CTI biopharma: Membership on an entity's Board of Directors or advisory committees; Geron: Consultancy, Membership on an entity's Board of Directors or advisory committees; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Jazz Pharmaceuticals: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servier: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Servio: Honoraria; DSI: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sumitomo Pharma: Consultancy, Membership on an entity's Board of Directors or advisory committees; Sobi: Consultancy, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Rigel: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Consultancy; BMS: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; BMS: Research Funding; Servio: Membership on an entity's Board of Directors or advisory committees. Garcia-Manero: Helsinn: Other: Personal fees; H3 Biomedicine: Research Funding; Merck: Research Funding; Novartis: Research Funding; Onconova: Research Funding; Genentech: Other: Personal fees; Curis: Research Funding; Janssen: Research Funding; Forty Seven: Research Funding; Astex: Other: Personal fees; Genentech: Research Funding; Astex: Research Funding; Aprea: Research Funding; Bristol Myers Squibb: Other: Personal fees, Research Funding; AbbVie: Research Funding; Helsinn: Research Funding; Amphivena: Research Funding. Della Porta: Bristol Myers Squibb: Consultancy.